Moderna's stock rallies 8% as deal over a patent dispute clears vaccine pipeline

A vial containing Moderna's COVID vaccine. A deal related to the vaccine's patents clears the way for the pharma company's vaccine pipeline. Shares of Moderna jumped more than 8% in the extended ...
National Academies of Sciences%2c Engineering%2c and Medicine

Responsible Science: Ensuring the Integrity of the Research Process

Fostering Integrity in Research identifies best practices in research and recommends practical options for discouraging and addressing research misconduct and detrimental research practices. An ad hoc ...

Louisiana bets big on ‘blue ammonia.’ Communities along Cancer Alley brace for the cost.

Floodlight reports Louisiana is investing in "blue ammonia," raising concerns among locals about health risks from proposed ...

Altamira to Exhibit at the 2026 AMPP Conference + Expo In Houston, Texas

We understand that today’s corrosion & integrity challenges demand more than traditional approaches. They require ...

Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations

Q4 2025 earnings call: 2026 revenue outlook, 22% commercial growth, cost cuts, margins & pipeline updates—read key takeaways.

Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

Anika Therapeutics, Inc. ( ANIK) Q4 2025 Earnings Call February 26, 2026 8:30 AM EST Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year-End Earnings Conference Call.